- Home
- XLO vs PYPD Comparison
XLO vs PYPD Comparison
Compare XLO & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XLO
- PYPD
- Stock Information
- Founded
- XLO 2016
- PYPD 2008
- Country
- XLO United States
- PYPD Israel
- Employees
- XLO N/A
- PYPD N/A
- Industry
- XLO Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- XLO Health Care
- PYPD Health Care
- Exchange
- XLO Nasdaq
- PYPD Nasdaq
- Market Cap
- XLO 35.7M
- PYPD 34.8M
- IPO Year
- XLO 2021
- PYPD 2020
- Fundamental
- Price
- XLO $0.75
- PYPD $3.37
- Analyst Decision
- XLO Buy
- PYPD Strong Buy
- Analyst Count
- XLO 2
- PYPD 5
- Target Price
- XLO $3.00
- PYPD $12.00
- AVG Volume (30 Days)
- XLO 946.5K
- PYPD 52.0K
- Earning Date
- XLO 11-06-2025
- PYPD 11-12-2025
- Dividend Yield
- XLO N/A
- PYPD N/A
- EPS Growth
- XLO N/A
- PYPD N/A
- EPS
- XLO N/A
- PYPD N/A
- Revenue
- XLO $15,001,000.00
- PYPD N/A
- Revenue This Year
- XLO $982.12
- PYPD N/A
- Revenue Next Year
- XLO N/A
- PYPD N/A
- P/E Ratio
- XLO N/A
- PYPD N/A
- Revenue Growth
- XLO 536.45
- PYPD N/A
- 52 Week Low
- XLO $0.62
- PYPD $2.30
- 52 Week High
- XLO $1.70
- PYPD $3.93
- Technical
- Relative Strength Index (RSI)
- XLO 60.31
- PYPD 44.08
- Support Level
- XLO $0.71
- PYPD $3.35
- Resistance Level
- XLO $0.78
- PYPD $3.54
- Average True Range (ATR)
- XLO 0.04
- PYPD 0.12
- MACD
- XLO 0.01
- PYPD -0.00
- Stochastic Oscillator
- XLO 64.03
- PYPD 16.67
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.